GLP-1 prescribing competency gap creates structural safety risk through primary care psychiatric drug misclassification

GLP-1 receptor agonists engage VTA, nucleus accumbens, insula, and prefrontal cortex to directly regulate reward pathways and reinforcement learning — making them functionally psychiatric drugs. However, they are prescribed primarily by primary care physicians for weight loss without psychiatric monitoring infrastructure. Dr. Sauvé states: 'If our field of psychiatry does not get a hundred percent ahead of how this GLP thing works, then we're going to be left behind.' The competency gap is structural: psychiatrists manage patients on GLP-1s they didn't prescribe, without understanding central mechanisms, dosing nuances, or psychiatric side effects. This creates a supervision gap for drugs that directly modulate dopaminergic reward circuits — the same circuits targeted by psychiatric medications. The gap exists because the drugs are classified and prescribed as metabolic agents despite their primary mechanism involving psychiatric circuitry. This is distinct from the general GLP-1 prescribing competency gap because it specifically concerns the mismatch between psychiatric mechanism and non-psychiatric prescriber training.

Extending Evidence

Source: Psychopharmacology Institute Q1 2026 Review

Psychopharmacology Institute Q1 2026 guidance establishes monthly monitoring using validated depression/suicidality tools and psychoeducation for mood lability, appetite changes, and suicidal ideation as the psychiatric-specific monitoring protocol. This protocol is disseminated through CME to psychiatrists but not systematically available to primary care prescribers.

Extending Evidence

Source: PMC systematic review + JAMA Psychiatry RCT

The 195% MDD risk signal from community-based cohort study (observational, confounded by indication) combined with AUD efficacy data (RCT, NNT 4.3) demonstrates that GLP-1 has complex psychiatric pharmacology requiring competency beyond metabolic prescribing. One mechanistic hypothesis: GLP-1 reduces reward salience (beneficial for addiction/cravings) but may reduce hedonic response broadly (potential depression pathway). This suggests behavioral health deployment requires psychiatric evaluation protocols, not just metabolic monitoring.